Skip to main content Back to Top
Advertisement

3/29/2024

Dacarbazine Injection

Products Affected - Description

    • Dacarbazine lyophilized powder for injection, Fresenius Kabi, 100 mg, vial, 1 count, NDC 63323-0127-10
    • Dacarbazine lyophilized powder for injection, Fresenius Kabi, 200 mg, vial, 1 count, NDC 63323-0128-20
    • Dacarbazine lyophilized powder for injection, Hikma, 200 mg, vial, 1 count, NDC 55390-0090-10
    • Dacarbazine lyophilized powder for injection, Teva, 200 mg, vial, 10 count, NDC 00703-5075-03

Reason for the Shortage

    • Fresenius Kabi has dacarbazine on shortage due to increased demand.
    • Hikma has dacarbazine on shortage due to increased demand.
    • Teva is not currently marketing dacarbazine.

Available Products

    • There is insufficient supply for usual ordering

Estimated Resupply Dates

    • Fresenius Kabi has dacarbazine 100 mg and 200 mg vials on back order and the company estimates a release date of late-April to early-May 2024 for the 100 mg vials and early- to mid-April 2024 for the 200 mg vials. Check wholesalers for inventory.
    • Hikma has dacarbazine 200 mg vials on allocation.

Alternative Agents & Management

    • Consider evaluating the health-care system's total supply of dacarbazine before beginning patients on combination chemotherapy regimens containing dacarbazine. If adequate supplies are not available, select an alternative regimen.
    • The choice of an alternative agent must be patient-specific and based on renal function, liver function, and the neoplasm type and location. No single agent can be substituted for dacarbazine.
    • Consult a Hematology/Oncology specialist for patient- and neoplasm-specific recommendations.
    • Refer to the ASHP Guidelines on Managing Drug Product Shortages for more guidance on developing a multidisciplinary plan when the supply must be allocated. https://www.ashp.org/-/media/assets/policy-guidelines/docs/guidelines/managing-drug-product-shortages.pdf
    • Refer to national guidelines such as those from the National Comprehensive Cancer Network (www.nccn.org) or American Society of Clinical Oncology (http://www.asco.org/) for additional information regarding therapeutic use.

Updated

Updated March 29, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created July 23, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.

ADVERTISEMENT